| Literature DB >> 34095123 |
Lingling Jiang1,2, Yan Qi2, Xianghan Kong2, Runnan Wang3, Jianfei Qi4, Francis Lin5, Xueling Cui3, Zhonghui Liu2.
Abstract
Activin A, a member of the transforming growth factor-beta (TGF-β) superfamily, contributes to tissue healing and fibrosis. As the innate tissue cells, fibroblasts also play an important role in wound healing and fibrosis. Herein, this study was aimed to investigate how activin A exhibited regulatory effects on adhesion and migration of fibroblasts. We found that activin A induced the migration of fibroblast cell line L929 cells in transwell chamber and microfluidic device. Activin A also promoted L929 cells adhesion, but did not affect L929 cells viability or proliferation. In addition, activin A induced α-SMA expression and TGF-β1 release, which were factors closely related to tissue fibrosis, but had no effect on IL-6 production, a pro-inflammatory cytokine. Furthermore, activin A elevated calcium levels in L929 cells and increased p-ERK protein levels. Activin A-induced migration of L929 cells was attenuated by ERK inhibitor FR180204. To conclude, these data indicated that activin A as a novel chemokine induced the chemotactic migration of L929 cells via ERK signaling and possessed the pro-fibrosis role. These findings provide a new insight into understanding of activin A in tissue fibrosis.Entities:
Keywords: ERK; activin A; fibroblasts; microfluidic device; migration
Year: 2021 PMID: 34095123 PMCID: PMC8175620 DOI: 10.3389/fcell.2021.660316
Source DB: PubMed Journal: Front Cell Dev Biol ISSN: 2296-634X
FIGURE 1Effects of activin A on adhesion and proliferation of L929 cells. (A) Real-time cell adhesion was assessed by RTCA in L929 cells subject to activin A at different concentrations for 4 h. ∗∗P < 0.01 compared with the 0 ng/ml control group. (B) MTT assay was performed to assess the viability of L929 cells treated with activin A at different concentrations for 24 h. Data represent mean ± SD (n = 6). (C) Real-time cell proliferation of L929 cells was assessed by RTCA in 70 h.
FIGURE 2Effect of activin A on migration of L929 cells. (A) The chemotactic migration of L929 cells to activin A (0–20 ng/mL) and CXCL12 (100 ng/mL) was analyzed by transwell chamber assay. Cell that passed through porous membrane of the chamber were stained with Giemsa. Scale bar = 50 μm. The graph showed the average number of Giemsa-stained cells in three separate experiments. ∗∗P < 0.01 compared with 0 ng/mL control group. (B) Images of L929 cells migration toward 10 ng/mL activin A gradient at different times were taken in the microfluidic device. Scale bar = 50 μm. (C) Images of L929 cells migration toward different concentrations activin A gradient (0–20 ng/mL) were taken in the microfluidic device at 0 and 20 h, respectively. Scale bar = 50 μm. The graph showed the average number and distance of migrating cells in the same size fields of the microfluidic device in three separate experiments. ∗P < 0.05 and ∗∗P < 0.01 compared with 0 ng/mL control group.
FIGURE 3Effects of activin A on wound healing in L929 cells. A scratch-wound was generated in monolayer L929 cells, and then cells were treated with activin A (0–20 ng/mL) for 24 h. The graph showed the degree of wound healing from three separate experiments. Scale bar = 100 μm.
FIGURE 4Pro-fibrosis role of activin A in L929 cells. (A) Representative images of L929 cells by Giemsa staining. L929 fibroblasts were treated with or without 10 ng/mL activin A for 24 h. (B) Western blotting analysis showed that activin A promoted α-SMA expression. The graph represented the relative levels of proteins in three separate experiments. The levels of α-SMA protein were normalized against GAPDH, and the results were shown as the fold-increase of the control. ∗∗P < 0.01 compared with 0 ng/mL control group. (C) L929 cells were incubated containing 0, 5, 10, or 20 ng/mL activin A for 24 h. Levels of TGF-β1 and IL-6 in the supernatant of cultured L929 cells were measured by ELISA. Data represent mean ± SD (n = 6). ∗∗P < 0.01 compared with 0 ng/mL control group.
FIGURE 5Effect of activin A on calcium signaling of L929 cells. (A) Kinetics of calcium signal was measured by the Fluo-4 intensity in L929 cells treated with 0–20 ng/mL activin A. (B) The graph showed the peak values of calcium signal upon stimulation under different concentrations activin A. The calcium level was represented by the Fluo-4 signal intensity normalized to the baseline (F/F0). The graph represented the results from three separate experiments. ∗P < 0.05 and ∗∗P < 0.01 compared with 0 ng/mL control group.
FIGURE 6Effects of activin A on ERK signaling in L929 cells. (A) Levels of p-ERK and ERK proteins were examined by Western blotting in L929 cells subject to activin A for 2 h. The graph represented the relative levels of proteins in three separate experiments. ∗∗P < 0.01 compared with 0 ng/mL control group. (B) L929 cells were seed in 12-well plates and pretreated for 1 h with 0.1% DMSO or 1 μmol/L FR180204 before treated for 2 h with or without 10 ng/mL activin A. Levels of p-ERK and ERK were examined by Western blotting. The graph represented the relative levels of proteins in three separate experiments. ∗P < 0.05 compared with 0.1% DMSO control group. (C) L929 cells were pretreated for 12 h with 0.1% DMSO or 1 μmol/L FR180204 and then cell migration toward 10 ng/mL activin A gradient was examined by microfluidic devices. ∗P < 0.05 compared with 0.1% DMSO control group.